Herbas VPB

Print
EN | LT
LT - A COMPOSITION COMPRISING A BENZAMIDE AND A TNFRSF AGONIST BINDING TO 4-1BB OR GITR, AND THE USE THEREOF IN THE TREATMENT OF CANCER.
EN - A COMPOSITION COMPRISING A BENZAMIDE AND A TNFRSF AGONIST BINDING TO 4-1BB OR GITR, AND THE USE THEREOF IN THE TREATMENT OF CANCER.

Legal status

Patent not validated

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 31/4184 (2013.01)
A61K 31/4184 (2006.01)
A61K 31/166 (2006.01)
C07D 401/04 (2013.01)
A61K 31/4164 (2006.01)
C07D 235/30 (2013.01)
C07C 259/10 (2006.01)
C07D 403/04 (2013.01)
C07D 235/30 (2006.01)
C07D 403/06 (2013.01)
A61K 35/00 (2006.01)
A61K 45/06 (2013.01)
A61K 9/08 (2006.01)
A61K 39/3955 (2013.01)
A61K 39/39558 (2013.01)
C07K 16/2818 (2013.01)
C07K 16/2878 (2013.01)
A61K2039/505 (2013.01)
A61K2039/507 (2013.01)
A61P 35/04 (2018.01)
A61P 35/00 (2018.01)
A61K2039/804 (2018.08)
A61K2039/812 (2018.08)
A61K 9/0014 (2013.01)
A61K 9/0019 (2013.01)
A61K 9/0024 (2013.01)
A61K 9/0043 (2013.01)
A61K 9/0053 (2013.01)
A61K 9/0073 (2013.01)
A61K 9/08 (2013.01)
European patent
(11) Number of the document 3544601
(13) Kind of document T
(96) European patent application number 17875035.2
Date of filing the European patent application 2017-11-24
(97) Date of publication of the European application 2019-10-02
(45) Date of publication and mention of the grant of the patent 2024-03-20
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/US2017/063195
Date 2017-11-24
PCT application publication
(87) Number WO 2018/098401
Date 2018-05-31
Priority applications
(30) Number Date Country code
201662426031 P 2016-11-23 US
Inventors
(72)
WANG, Tong , US
GATELY, Stephen , US
GONZALES, Paul , US
Grantee
(73) Translational Drug Development, LLC , 13208 East Shea Boulevard Suite 100, Scottsdale, Arizona 85259, US
Title
(54) A COMPOSITION COMPRISING A BENZAMIDE AND A TNFRSF AGONIST BINDING TO 4-1BB OR GITR, AND THE USE THEREOF IN THE TREATMENT OF CANCER.
  A COMPOSITION COMPRISING A BENZAMIDE AND A TNFRSF AGONIST BINDING TO 4-1BB OR GITR, AND THE USE THEREOF IN THE TREATMENT OF CANCER.